ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PCRX Pacira BioSciences Inc

27.21
-0.11 (-0.40%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Pacira BioSciences Inc NASDAQ:PCRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.11 -0.40% 27.21 25.63 29.30 27.77 27.05 27.68 247,316 00:50:13

Statement of Changes in Beneficial Ownership (4)

20/11/2017 11:45pm

Edgar (US Regulatory)


FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Williams Kristen Marie
2. Issuer Name and Ticker or Trading Symbol

Pacira Pharmaceuticals, Inc. [ PCRX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
CAO and General Counsel
(Last)          (First)          (Middle)

C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300
3. Date of Earliest Transaction (MM/DD/YYYY)

11/16/2017
(Street)

PARSIPPANY, NJ 07054
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   11/16/2017     M (1)    2143   A $25.37   23455   D    
Common Stock   11/16/2017     S (1)    2143   D $40.01   21312   D    
Common Stock   11/17/2017     M (1)    7857   A $25.37   29169   D    
Common Stock   11/17/2017     S (1)    7857   D $40.00   21312   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   $25.37   11/16/2017     M         2143      (2) 3/5/2023   Common Stock   2143   $0.00   7857   D    
Stock Option (Right to Buy)   $25.37   11/17/2017     M         7857      (2) 3/5/2023   Common Stock   7857   $0.00   0   D    

Explanation of Responses:
(1)  The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
(2)  The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Williams Kristen Marie
C/O PACIRA PHARMACEUTICALS, INC.
5 SYLVAN WAY, SUITE 300
PARSIPPANY, NJ 07054


CAO and General Counsel

Signatures
/s/ Kristen Williams 11/20/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1 Year Pacira BioSciences Chart

1 Year Pacira BioSciences Chart

1 Month Pacira BioSciences Chart

1 Month Pacira BioSciences Chart

Your Recent History

Delayed Upgrade Clock